Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 7, 2012; 18(41): 5879-5888
Published online Nov 7, 2012. doi: 10.3748/wjg.v18.i41.5879
Table 1 Baseline profiles of the study population (mean ± SD)
VariableOverall cohort (n = 561)Derivation group (n = 374)Confirmatory group (n = 187)
Demographic feature
Age (yr)59.1 ± 10.959.1 ± 10.859.5 ± 11.3
Sex (female/male)302/259201/173101/86
Weight (kg)59.8 ± 11.459.9 ± 11.558.5 ± 10.9
BMI (kg/m2)23.2 ± 3.323.2 ± 3.423.2 ± 3.2
Height (cm)160.3 ± 9.0160.4 ± 9.1158.5 ± 8.7
BSA (m2)1.62 ± 0.181.62 ± 0.181.59 ± 0.18
Laboratory data
ALT (IU/L)63 ± 5463 ± 5658 ± 47
GGT (IU/L)58 ± 6356 ± 6058 ± 72
Albumin (g/dL)4.1 ± 0.44.1 ± 0.44.1 ± 0.3
Creatinine (mg/dL)0.70 ± 0.160.70 ± 0.170.70 ± 0.17
WBC count (× 103/mL)5.0 ± 1.55.0 ± 1.55.1 ± 1.4
Hemoglobin (g/dL)13.7 ± 1.513.7 ± 1.513.8 ± 1.3
Platelet count (× 104/mL)16.7 ± 5.716.5 ± 5.717.0 ± 6.2
Estimated calculation value
Ccr (mL/min)91.8 ± 27.991.6 ± 28.087.9 ± 25.6
GFR (mL/min/1.73 m2)77.5 ± 16.879.6 ± 17.078.2 ± 15.9
CL/F (L/h)11.3 ± 5.411.2 ± 5.310.9 ± 5.1
Liver histopathology
Stage of fibrosis 0-1/2/3-4221/131/161146/89/10775/42/54
Grade of inflammation 1/2/3267/222/19170/156/1497/66/5
SNP genotype
rs1127354 CC/CA/AA431/114/16289/75/10142/39/6
rs6051702 AA/AC/CC388/158/15260/104/10128/54/5
Treatment
Ribavirin dosage (mg/kg/d)11.4 ± 1.511.3 ± 1.911.4 ± 1.9
Peg-IFN α-2a/-2b82/47952/32230/157
Virology
Viral load (log10 IU/mL)6.2 ± 0.86.2 ± 0.86.2 ± 0.8
Table 2 Time-course changes in hemoglobin concentration from baseline
Week 2 of treatmentWeek 4 of treatment
Overall cohort
mean (SD), g/dL-1.12 (1.13)-2.31 (1.39)
Median (25th–75th quartile), g/dL-1.05 (-1.8 to -0.3)-2.3 (-3.2 to -1.3)
Derivation group
mean (SD), g/dL-1.09 (1.11)-2.27 (1.40)
Median (25th–75th quartile), g/dL-1.0 (-1.8 to -0.3)-2.3 (-3.1 to -1.3)
Confirmatory group
mean (SD), g/dL-1.18 (1.17)-2.33 (1.37)
Median (25th–75th quartile), g/dL-1.1 (-1.95 to -0.4)-2.3 (-3.3 to -1.35)
Table 3 Pretreatment variables influencing significant hemoglobin decline in the derivation group
VariableP value
OR (95% CI)
Univariate analysisMultivariate analysis
Age (yr)0.110
Sex (female vs male)0.0163
Weight (kg)5.18 × 10-3
BMI5.93 × 10-3
Height (cm)0.153
BSA (m2)0.0139
ALT (IU/L)0.114
GGT (IU/L)0.118
Albumin (g/dL)6.88 × 10-3
Creatinine (mg/dL)4.71 × 10-4
WBC count (× 103/mL)0.147
Hemoglobin (g/dL)7.75 × 10-81.29 × 10-91.89 (1.54-2.32)
Platelet count (× 104/mL)0.558
Ccr (mL/min)0.140
GFR (mL/min/1.73 m2)5.69 × 10-46.46 × 10-40.959 (0.942-0.977)
CL/F (L/h)0.814
Stage of fibrosis0.641
Grade of inflammation0.570
rs1127354 (CC vs CA/AA)8.04 × 10-101.60 × 10-728.26 (8.10-98.62)
rs6051702 (AA vs AC/CC)0.372
RBV dosage (mg/kg/d)0.419
Peg-IFN α (2a vs 2b)0.360
Viral load (log10 IU/mL)0.355